Skip to content


    DEA Class; Rx

    Common Brand Names; Xalatan, Xelpros, Iyuzeh

    • Antiglaucoma, Prostaglandin Agonists

    Ophthalmic analog of prostaglandin F2-alpha
    Used for increased intraocular pressure in patients with open-angle glaucoma or ocular hypertension
    Associated with increased pigmentation of iris, eyelid, and eyelashes

    Indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

    Hypersensitivity to latanoprost, benzalkonium chloride, or other components of product

    • Increase in brown pigmentation of the iris (15.5%)
    • Blurred vision (5-15%)
    • Burning and stinging (5-15%)
    • Foreign body sensation (5-15%)
    • Itching (5-15%)
    • Punctate epithelial keratopathy (5-15%)
    • Conjunctival hyperemia (5-15%)
    • Upper respiratory tract infection/cold/flu (4%)
    • Dry eye (1-4%)
    • Excessive tearing (1-4%)
    • Eye pain (1-4%)
    • Lid crusting (1-4%)
    • Lid edema (1-4%)
    • Lid erythema (1-4%)
    • Lid discomfort/pain (1-4%)
    • Photophobia (1-4%)
    • Chest pain/angina pectoris (1-2%)
    • Muscle/joint/back pain (1-2%)
    • Rash/allergic skin reactions (1-2%)

    Macular edema, including cystoid macular edema, reported; Caution caution with aphakic and pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema

    Caution in active intraocular inflammation (eg, iritis/uveitis); generally not for use in patients with active intraocular inflammation; may exacerbate inflammation

    Reactivation of herpes simplex keratitis reported; administer with caution in patients with a history of herpetic keratitis; avoid in cases of active herpes simplex keratitis because inflammation may be exacerbated

    Take contact lenses out when applying, reinsert at least 15 min later

    Bacterial keratitis may result from inadvertent contamination of multidose ophthalmic solutions

    Gradual changes in eyelashes and vellus hair (eg, increased length, thickness, pigmentation, number of lashes or hairs, and misdirected growth of eyelashes) may occur; changes are usually reversible upon discontinuation of treatment

    May permanently change brown pigmentation of the iris, eyelid skin, and eyelashes; after discontinuation, pigmentation of the iris is likely to be permanent, while pigmentation of periorbital tissue and eyelash changes may be reversible in some patients; inform patients of possibility of increased pigmentation; continue treatment in patients who develop noticeably increased iris pigmentation and examine them regularly

    There are no adequate and well-controlled studies in pregnant women

    Only use during pregnancy if potential benefits justifies potential risks to the fetus

    Not known whether this drug or its metabolites are excreted in human milk; because many drugs are excreted in human milk, exercise caution drug is administered to a nursing woman


    1 drop/day per affected eye.


    1 drop/day per affected eye.


    Safety and efficacy have not been established.


    Safety and efficacy have not been established.


    Safety and efficacy have not been established.


    Safety and efficacy have not been established.


    ophthalmic solution

    • 0.005% (2.5mL) (Xalatan)

    ophthalmic solution, preservative-free

    • 0.005% in single-dose containers (Iyuzeh)

    ophthalmic emulsion

    • 0.005% (2.5mL) (Xelpros)